Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 65.50
Bid: 64.00
Ask: 67.00
Change: 0.00 (0.00%)
Spread: 3.00 (4.688%)
Open: 65.50
High: 65.50
Low: 65.50
Prev. Close: 65.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

16 Jan 2006 07:00

Torex Retail PLC16 January 2006 Monday 16th January 2006 Torex Retail Plc Pre-close Update & Board Change Torex Retail Plc ("Torex Retail" or "the Group"), a leading supplier of ITsolutions to retailers worldwide, is pleased to announce that it expects toreport trading for the year ended 31 December 2005 in line with marketexpectations. In addition to this, the Group are pleased to announce thefollowing:- Trading UK Torex Retail continued to experience a strong second half trading performance inthe UK, the Group's largest market, with a number of notable achievements: • A record number of LUCAS product sales, primarily to the Alphamericcustomer base, reflecting the successful integration of that business and fullyconsistent with their corporate strategy; • New business success with blue chip retailers particularly forperformance management, petrol and retail pharmacy solutions; • Development of record sales pipeline for 2006 particularly inhospitality where the level of new enquiries from major retailers is verypositive; • Building on its historical strength within the independent petroleumsector, the Group is increasingly winning business from the major oil companiesand forecourt supermarkets. This market is expected to demonstrate stronggrowth in 2006. The level of demand from UK retailers for new IT systems remains strong. TheBritish Retail Consortium reported both December 2005 total sales 6.2% ahead of2004 and sales for the whole of the last quarter up 4.1% on 2004, representingthe best December since 2001. The Board of Torex Retail are confident that thestrong Christmas trading will further encourage retailers to pursue planned ITinvestments, driven by the need to gain competitive advantage and replaceoutdated technology platforms. USA In the USA, the largest retail IT market in the world (estimated at betweenUS$4-5bn in software and services alone) Torex Retail is continuing to penetratethe market, with RSS and Systech now being fully integrated into the newlylaunched Torex Retail North America. The outlook for the market is verypositive, with the retail and hospitality systems sectors experiencing stronggrowth as retailers replace systems that were last updated pre the Millennium. Against this backdrop of buoyant market conditions there are still a number ofopportunities for further consolidation of the US retail and hospitality ITmarkets, which is fully consistent with the Group's strategy of buildingcritical mass and providing cross-selling opportunities to drive future organicgrowth. Europe The Group has continued to win a number of important new business wins for bothits LUCAS and OSCAR products. The Group is now the market leader for retail ITsolutions in Continental Europe, with a large customer base and very strongdelivery capability. This puts the Group in an excellent position to takeadvantage of the upturn in the market as the POS replacement cycle (currentlybeing actively experienced in the UK and particularly the US) increasinglyimpacts in Europe. Integration Update Good progress had been made with the integration of companies acquired duringthe year with XN Checkout, Anker and Systech having now been completely absorbedinto the Group's operating infrastructure. The restructuring of the Group's UKand European business following the acquisition of Anker continues to run aheadof initial expectations, both in terms of the quantum and timing of overheadsavings. It is now anticipated that the total annualised cost savings will be in excessof £12 million (over 2x initially reported) with related restructuring costs inthe region of £15 million in 2005 and £5 million in 2006, representing a 20month payback. These savings help to underpin the improvement in operatingprofit in 2006, and particularly 2007 and beyond. Board Change It is announced that by mutual agreement Michael Meade, who joined the Companyon 1 November 2005, is for personal reasons to step down from the Board ofdirectors. The Board has identified a replacement Group Finance Director, whois currently employed within a publicly quoted company. The new appointment isexpected to be confirmed at the time of the Group's preliminary results'announcement. In the meantime, responsibility for the finance function will bein the very capable hands of Mark Pearman, who was the Group Finance Director ofTorex PLC between 1998 and 2001. Michael will be leaving the Board withimmediate effect. Chris Moore, Chairman of Torex Retail, commented: "The Group is exceptionally well positioned for future growth in 2006 with astrong order book and good visibility of earnings, supported by a high level ofrecurrent revenues. During 2005 the Group's strategic focus was on acquisition-driven growth tobuild our customer base and critical mass in our chosen markets. In 2006, theemphasis will be to aggressively drive the benefits from our 6,000 strongcustomer base and "best of breed" product portfolio to achieve increased organicgrowth. This focus, combined with a limited number of carefully targetedstrategically important acquisitions, will continue to deliver increasedshareholder value in 2006 and beyond. On a personal note, and on behalf of the Board, I would like to wish MichaelMeade every future success in whichever field he decides to continue his career.At the same time I am delighted that we have identified a strong andexperienced replacement and I have every confidence in Mark Pearman, who willoversee our Finance function in the interim period." Torex Retail Plc expects to announce its 2005 preliminary results in early March2006. Enquiries: Chris Moore, ChairmanTorex Retail Plc0870 300 6061 Ginny Pulbrook / Seb Hoyle / Lucie HollowayCitigate Dewe Rogerson020 7638 9571 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
17th Oct 20143:35 pmRNSInitial Clinical Trial Results
10th Sep 20149:00 amRNSdCELL® technology presented at Royal Society event
30th Jul 20147:00 amRNSUK meniscus clinical trial & DermaPure US updates
25th Jul 20147:00 amRNSTissue Regenix adds European bladder matrix patent
18th Jul 201411:11 amRNSIssue of equity and total voting rights
27th Jun 20143:06 pmRNSResult of AGM
12th Jun 20147:00 amRNSTissue Regenix announces launch of DermaPure in US
22nd May 20147:00 amRNSPreliminary Decision to Approve "Q" Code Request
20th May 20147:00 amRNSDeferred Annual Bonus Award
19th May 201410:21 amRNSAnnual Report & Accounts and Notice of AGM
19th May 20147:00 amRNSPreliminary results for year ended 31 January 2014
16th May 20141:00 pmRNSTissue Regenix adds US patent
12th May 201411:00 amRNSNotice of Preliminary Results
30th Apr 20145:14 pmRNSHolding(s) in Company
28th Apr 20147:00 amRNSTissue Regenix adds Chinese patent
24th Apr 20148:40 amRNSHolding(s) in Company
4th Feb 20143:03 pmRNSIssue of Share Options
31st Jan 20141:11 pmRNSHolding(s) in Company
14th Jan 20145:22 pmRNSIssue of equity and total voting rights
9th Jan 201411:11 amRNSIssue of equity and total voting rights
19th Dec 20137:00 amRNSTissue Regenix to attend JPMorgan Healthcare Event
12th Dec 20137:00 amRNSTissue Regenix signs US distribution agreements
22nd Nov 20137:00 amRNSDirector Share Purchase
29th Oct 20137:00 amRNSPresentation at Proactiveinvestors Forum in Dublin
28th Oct 20134:49 pmRNSDirector Share Purchase
21st Oct 20137:00 amRNSPublication of DermaPure UK trial results
17th Oct 20134:41 pmRNSHolding(s) in Company
17th Oct 20134:41 pmRNSHolding(s) in Company
17th Oct 20134:41 pmRNSHolding(s) in Company
14th Oct 20137:00 amRNSTissue Regenix USA successful technology transfer
8th Oct 20137:00 amRNSInterim Results for six months ended 31 July 2013
12th Aug 20137:00 amRNSTissue Regenix USA Appoints VP of Marketing
6th Aug 20139:41 amRNSHolding(s) in Company
5th Aug 20137:00 amRNSTissue Regenix USA Appoints VP of Operations
29th Jul 20138:45 amRNSTissue Regenix Key Appointment at USA Subsidiary
25th Jul 20134:59 pmRNSHolding(s) in Company
17th Jul 20137:00 amRNSAppointment of Non-Executive Director
10th Jul 20137:00 amRNSAppointment of Non-Executive Director
18th Jun 20137:00 amRNSTissue Regenix advances US commercialisation
14th Jun 201312:43 pmRNSResult of AGM
14th Jun 20137:00 amRNSPresentation of dCELL at heart valve event
28th May 20137:00 amRNSAppointment of Business Development Manager
14th May 20133:47 pmRNSAnnual Report and Notice of AGM
13th May 20137:00 amRNSPreliminary results for the year ended 31 Jan 2013
3rd May 20137:00 amRNSNotice of Results
2nd May 20137:00 amRNSResults of dCELL Dermis trial
29th Apr 20137:00 amRNSChange of Nominated Adviser and Broker
16th Apr 20137:00 amRNSApproval for start of clinical research trial
2nd Apr 20137:00 amRNSTissue Regenix makes appointment to US subsidiary
11th Mar 20137:00 amRNSDirector Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.